Abstracts tagged "quality of life"

Abstract Number: 0521 • ACR Convergence 2023
Work Productivity Improved in Patients with Axial Spondyloarthritis Receiving Bimekizumab Treatment over 52 Weeks: Results from Two Phase 3 Studies
Martin Rudwaleit¹, Victoria Navarro-Compán², Atul Deodhar³, Maureen Dubreuil⁴, Michael Frank Mørup⁵, Vanessa Taieb⁶, Christine de la Loge⁷, Carmen Fleurinck⁸, Ute Massow⁹, Thomas Vaux¹⁰ and Annelies Boonen¹¹, ¹University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ²Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ³Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, ⁴Department of Rheumatology, Boston University School of Medicine, Milton, MA, ⁵UCB Pharma, Copenhagen, Denmark, ⁶UCB Pharma, Colombes, France, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Oosterzele, Belgium, ⁹UCB Pharma, Monheim am Rhein, Germany, ¹⁰UCB Pharma, Slough, United Kingdom, ¹¹Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, Netherlands
Background/Purpose: The clinical manifestations of axial spondyloarthritis (axSpA) limit physical function and work productivity, posing an economic burden to patients (pts) and society.1 Bimekizumab (BKZ),…
Abstract Number: 1127 • ACR Convergence 2023
Factors Associated with Vision-Related Quality of Life in Patients with Non-infectious Uveitis: A Longitudinal Analysis
Maria Paula Alvarez Hernandez¹, Inés Pérez Sancristóbal¹, Alfredo Madrid García², Lara Borrego Sanz³, Cristina Hormigos martín¹, Beatriz García Tirado³, Mayte Ariño Gutiérrez³, Cristina lajas Petisco¹, Pedro Arriola Villalobos³, Esperanza Pato Cour³ and Luis Rodríguez Rodríguez¹, ¹Hospital Clinico San Carlos, Madrid, Spain, ²Fundación Investigación Biomédica Hospital Clínico San Carlos, Madrid, Spain, ³Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: Non-infectious uveitis (NIU) are characterized by inflammation of the middle layer of the eye wall and have a significant impact on patients' visual-related quality…
Abstract Number: 1836 • ACR Convergence 2023
Embracing a Biopsychosocial Approach to Fibromyalgia-like Symptoms in People with SLE: Insights from the Type 2 SLE Consortium
Jennifer Rogers¹, Megan Clowse² and Amanda Eudy³, ¹Duke University, Durham, NC, ²Duke University, Chapel Hill, NC, ³Duke University, Raleigh, NC
Background/Purpose: Patients with SLE experience distressing fibromyalgia-like symptoms of fatigue, widespread pain, mood disturbance, and brain fog that negatively impact quality of life and are…
Abstract Number: 2249 • ACR Convergence 2023
Bimekizumab-Treated Patients with Active PsA Showed Sustained Improvement in Disease Symptoms Assessed by the PsA Impact of Disease (PsAID)-12 Questionnaire: 1-Year Results Reported from Two Phase 3 Studies
Dafna Gladman¹, Laura Coates², Maarten de Wit³, Alexis R Ogdie⁴, Ana-Maria Orbai⁵, Barbara Ink⁶, Vanessa Taieb⁷, Jérémy Lambert⁸ and Laure Gossec⁹, ¹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²University of Oxford, Oxford, United Kingdom, ³Patient Research Partner, Stichting Tools, Amsterdam, Netherlands, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Colombes, France, ⁸UCB Pharma, Irigny, France, ⁹Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: The PsA Impact of Disease‑12 (PsAID‑12) questionnaire is a patient (pt)-reported outcome measure assessing the impact of PsA on 12 physical, social, and psychological…
Abstract Number: PP17 • ACR Convergence 2023
Utilizing Support Networks to Improve Patient Outcomes
Brian Vogel, Lupus and Allied Diseases Association, Inc., San Diego, CA
Background/Purpose: In 2006, I realized I was gay and identified as LGBTQIA but did not come out. In 2008, I began experiencing chronic widespread pain,…
Abstract Number: 0146 • ACR Convergence 2023
Sexual Health and Self-Perception in Rheumatologic Patients: Has Your Rheumatologist Ever Talked to You About Sexual Health?
Luis Vega Sevilla¹, Griselda Serna-Peña², Diana Paola Flores-Gutierrez³, Jesus Alberto Cardenas-De la Garza⁴, Dionicio A. Galarza-Delgado⁵ and Ivan Hernandez Galarza⁶, ¹Hospital Universitario UANL, Garcia, Mexico, ²Universidad Autónoma de Nuevo León, Guadalupe, Mexico, ³Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, ⁵Hospital Universitario UANL, Monterrey, Mexico, ⁶University Hospital, UANL, San Pedro Garza Garcia, Mexico
Background/Purpose: There's a high prevalence of sexual dysfunction (SD) in patients with rheumatic diseases (RD). Studies show that it goes from a 36% to a…
Abstract Number: 0525 • ACR Convergence 2023
Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies
Marina Nighat Magrey¹, Marleen van de Sande², Maxime Breban³, Filip Van den Bosch⁴, Carmen Fleurinck⁵, Ute Massow⁶, Natasha De Peyrecave⁷, Thomas Vaux⁸, Xenofon Baraliakos⁹ and Helena Marzo-Ortega¹⁰, ¹Case Western Reserve University, University Hospitals, Cleveland, OH, ²Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands, ³CHU Ambroise-Paré, Boulogne-Billancourt, Paris, France, ⁴Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ⁵UCB Pharma, Oosterzele, Belgium, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Slough, United Kingdom, ⁹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ¹⁰NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: In patients (pts) with axial spondyloarthritis (axSpA), tumor necrosis factor inhibitors (TNFi) are the usual first line biologic treatment, yet many pts may experience…
Abstract Number: 1170 • ACR Convergence 2023
Damage Accrual in Idiopathic Inflammatory Myopathies: Data from a Monocentric Cohort and Impact on Patients’ Quality of Life
Chiara Cardelli¹, Simone Barsotti², Elenia Laurino¹, Michele Diomedi¹, Federico Fattorini¹, Alessandra Tripoli¹, Linda Carli¹ and Marta Mosca¹, ¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ²Internal Medicine, Ospedale di Livorno, Pisa, Italy
Background/Purpose: Although the prognosis of Idiopathic Inflammatory Myopathies (IIMs) has noticeably improved over time, their chronicity may still expose a considerable number of patients to…
Abstract Number: 1838 • ACR Convergence 2023
The Burden of Dysautonomia in Patients Suffering from Pathologies Associated with Generalized Joint Hypermobility
Alizée Perrein¹, Fabien Pontille¹, Paul Decker², david Attali³, Thomas Moulinet⁴ and Roland Jaussaud⁵, ¹Département de Médecine interne et immunologie clinique, Université de Lorraine / CHRU de Nancy, Vandoeuvre-les-Nancy, France, ²Nancy hospital, France, Nancy, France, ³Université Paris Cité, Laboratoire Psychopathologie et Processus de Santé, Boulogne-Billancourt, France, ⁴Department of Internal Medicine, Centre hospitalier universitaire de Nancy, Nancy, France, ⁵Département de Médecine interne et immunologie clinique, Université de Lorraine / CHRU de Nancy, Vandoeuvre Les Nancy, France
Background/Purpose: Hypermobility spectrum disorders (HSD) and hypermobile Ehlers Danlos syndrome (hEDS) are among the conditions associated with generalized joint hypermobility (GJH). Alongside myofascial and skeletal…
Abstract Number: 2250 • ACR Convergence 2023
Bimekizumab Impact on Health-Related Quality of Life and Physical Function in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD‑Naïve or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3, Randomized Studies
Dafna Gladman¹, Laure Gossec², M. Elaine Husni³, Lars Erik⁴, Paolo Gisondi⁵, Alice B. Gottlieb⁶, Diamant Thaçi⁷, Barbara Ink⁸, Rajan Bajracharya⁸, Jérémy Lambert⁹, Nikos Lyris⁸, Jason Coarse¹⁰ and William R Tillett¹¹, ¹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France, ³Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH, ⁴Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ⁵Università di Verona, Verona, Italy, ⁶Icahn School of Medicine at Mount Sinai, New York, NY, ⁷Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁸UCB Pharma, Slough, United Kingdom, ⁹UCB Pharma, Irigny, France, ¹⁰UCB Pharma, Morrisville, NC, ¹¹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: PsA has a substantial negative impact on patient (pt) health-related quality of life (HRQoL);1 symptom control, preventing structural damage, and normalizing physical and social…
Abstract Number: 0148 • ACR Convergence 2023
Recreational Activities in Adults with Rheumatoid Arthritis: Relevance, Difficulty, and Associations with Clinical Outcomes
Sarah Novroski¹, Chris Lane¹, Joshua Torrey² and Louise Thoma³, ¹UNC Chapel Hill, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³University of North Carolina, Chapel Hill, NC
Background/Purpose: Rheumatoid arthritis (RA) can limit one's ability to participate in recreational activities. Participation in recreational activities enhances quality of life, yet limited literature addresses…
Abstract Number: 0526 • ACR Convergence 2023
Bimekizumab Improved Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 52-Week Results from Two Phase 3 Studies
Maureen Dubreuil¹, Karl Gaffney², Jonathan Kay³, Victoria Navarro-Compán⁴, Christine de la Loge⁵, Alicia Ellis⁶, Carmen Fleurinck⁷, Ute Massow⁸, Vanessa Taieb⁹ and Atul Deodhar¹⁰, ¹Department of Rheumatology, Boston University School of Medicine, Milton, MA, ²Norfolk and Norwich University Hospital NHS Trust, Norfolk, United Kingdom, ³Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA, ⁴Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁵UCB Pharma, Brussels, Belgium, ⁶UCB Pharma, Raleigh, NC, ⁷UCB Pharma, Oosterzele, Belgium, ⁸UCB Pharma, Monheim am Rhein, Germany, ⁹UCB Pharma, Colombes, France, ¹⁰Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR
Background/Purpose: Axial spondyloarthritis (axSpA) severely impairs physical function and health-related quality of life (HRQoL).1 Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in…
Abstract Number: 1201 • ACR Convergence 2023
Frailty and Its Impact on Patient Reported Outcomes in Polymyalgia Rheumatica
Patricia Harkins¹, Sharon Cowley², David Kane³ and Richard Conway⁴, ¹St James's Hospital, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Ireland, ³Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland, ⁴Trinity College Dublin, Dublin, Ireland
Background/Purpose: Frailty is an increasingly important construct in the field of rheumatology, aiding the identification of individuals with increased vulnerability to accelerated clinical decline and…
Abstract Number: 1846 • ACR Convergence 2023
A Longitudinal Study: The Benefits of Non-Pharmacological Approaches to Improve Self-Reported Pain, Stiffness, and Fatigue in Individuals with Musculoskeletal Disorders
Titilayo Adeniran, Bertilia Trieu, Claudia Zurlini, Bonnie McGrath, Linda Roberts, Pamela Sanchez-Villagomez, Vilma Briones, Robyn Wiesel, Sandra Goldsmith and Laura Robbins, Hospital for Special Surgery, New York, NY
Background/Purpose: Musculoskeletal disorders are a leading cause of disability worldwide, with low back pain being one of the primary causes. The World Health Organization (WHO)…
Abstract Number: 2259 • ACR Convergence 2023
The Effects of Systematic Lupus Erythematosus Related Cognitive Impairments on Activities of Daily Living and Life Role Participation: A Qualitative Framework Study
Michelle Barraclough¹, Aaron Howe², Ana Soberanis², Mahta Kakvan³, Vijay Chattu², Ali Bani-Fatemi², Lisa Engel⁴, Michelle Vitti⁵, Emily Nalder², Yael Groverover⁶, Monique Gignac⁷, Dennisse Bonilla¹, Wils Nielsen⁸, Nicole Anderson⁹, Carmela Tartaglia¹⁰, Behdin Nowrouzi-Kia² and Zahi Touma², ¹University Health Network, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University of Manitoba, Institute for Work & Health, Winnipeg, MB, Canada, ⁵Michelle Vitti Psychotherapy and Counselling, Toronto, ON, Canada, ⁶NYU Steinhardt, New York, NY, ⁷Institute for Work & Health, Toronto, ON, Canada, ⁸University of Toronto, Markham, ON, Canada, ⁹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ¹⁰Krembil Brain Institute, University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) in systemic lupus erythematosus (SLE) negatively impacts health-related quality of life leading to activity limitations. This qualitative study aimed to (1)…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].